Prescient Therapeutics (FRA:UDD) Dividends Paid: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Prescient Therapeutics Dividends Paid?

Prescient Therapeutics FRA:UDD +64.52% Dividends Paid is €0.00 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Prescient Therapeutics's Dividends Paid for the six months ended in Jun. 2026 was €0.00 Mil.

Prescient Therapeutics's Dividends Paid for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil.

Prescient Therapeutics Dividends Paid Related Terms

Prescient Therapeutics Dividends Paid Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Dividends Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Dividends Paid Chart

Prescient Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Dividends Paid
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Dividends Paid Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Dividends Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Dividends Paid represents dividend paid to the investors in the direct cash flow method.

Dividends Paid for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividends Paid →
What does a Dividends Paid of €0.00 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Dividends Paid of €0.00 Mil as of Jun. 2026. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Dividends Paid too high?
Prescient Therapeutics' current Dividends Paid is €0.00 Mil.
How does Prescient Therapeutics' Dividends Paid compare to VRTX and REGN?
Prescient Therapeutics' Dividends Paid of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends Paid for a Biotechnology company?
A good Dividends Paid depends on the Biotechnology industry context. However, Dividends Paid should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends Paid mean?
A high Dividends Paid can signal that a stock is expensive relative to its fundamentals. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Prescient Therapeutics and its competitors. Prescient Therapeutics's current Dividends Paid is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Dividends Paid of €0.00 Mil. The current Dividends Paid is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends Paid calculated?
Dividends Paid is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Dividends Paid is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.